Share Search
Visit the Share Search
Mediclinic still expects revenue, EBITDA growth across divisions
27th Jul 2021 08:41
(Sharecast News) - Private hospital operator Mediclinic said on Tuesday that for the year to the end of March 2022, it still expects to deliver growth in revenue and EBITDA across all three of its divisions, amid solid demand.
In an update ahead of its annual meeting, the company said underlying demand for its services has been strong and the year-to-date operating performance is in line with expectations.
Mediclinic said that in FY22, pre-Covid-19 seasonal trends which impact operating performance are expected to return and be reflected in the half-year results of its Swiss business, Hirslanden, and Mediclinic Middle East.
"With the ongoing pandemic, varied pace of vaccine rollouts and planning assumptions of further waves and variants causing continued uncertainty on the shape of the recovery, Mediclinic remains cautious as to the full impact of Covid-19 on near-term operating performance," it said.
"In line with the outlook statement provided as part of the 2021 financial year results, and given the group's focus on operational and cost efficiencies, it does not anticipate any long-term structural impediments in returning EBITDA margins at Hirslanden and Mediclinic Southern Africa to pre-pandemic levels."
At Mediclinic Middle East, margins are expected to continue to increase gradually as it grows its presence across the region, supported by recent expansion and upgrade projects in Dubai and Abu Dhabi.
In an update ahead of its annual meeting, the company said underlying demand for its services has been strong and the year-to-date operating performance is in line with expectations.
Mediclinic said that in FY22, pre-Covid-19 seasonal trends which impact operating performance are expected to return and be reflected in the half-year results of its Swiss business, Hirslanden, and Mediclinic Middle East.
"With the ongoing pandemic, varied pace of vaccine rollouts and planning assumptions of further waves and variants causing continued uncertainty on the shape of the recovery, Mediclinic remains cautious as to the full impact of Covid-19 on near-term operating performance," it said.
"In line with the outlook statement provided as part of the 2021 financial year results, and given the group's focus on operational and cost efficiencies, it does not anticipate any long-term structural impediments in returning EBITDA margins at Hirslanden and Mediclinic Southern Africa to pre-pandemic levels."
At Mediclinic Middle East, margins are expected to continue to increase gradually as it grows its presence across the region, supported by recent expansion and upgrade projects in Dubai and Abu Dhabi.